Clinical

Dataset Information

0

A phase II clinical study of cancer vaccine with Survivin helper peptide for patients with advanced/recurrent colorectal cancers


ABSTRACT: Interventions: 1st and 2nd duration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil; 0.02 KE), at every two weeks, repeated 4 times 3rdduration of therapy: Subcutaneous injection of Survivin-hepler pepitde (1 mg) vaccine, mixed with Montanide and OK432 (Picibanil; 0.02 KE), at every four weeks, repeated 4 times Primary outcome(s): Tumor response: Disease control rate (DCR), best over- all response assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) after Survivin helper peptide vaccine Study Design: Single arm Non-randomized

DISEASE(S): Survivin-expressing Advanced/recurrent Colorectal Cancer Patients Or Patients Who Refuse Standard Cancer Therapy

PROVIDER: 2622923 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2008-06-14 | E-GEOD-6388 | biostudies-arrayexpress
2014-09-18 | GSE49325 | GEO
2014-01-08 | E-GEOD-53230 | biostudies-arrayexpress
| 2620402 | ecrin-mdr-crc
| 2621744 | ecrin-mdr-crc
| 2623214 | ecrin-mdr-crc
2019-12-10 | GSE135609 | GEO
2021-05-17 | E-MTAB-10309 | biostudies-arrayexpress
2020-06-30 | GSE139225 | GEO
2011-11-23 | GSE25680 | GEO